ClinicalTrials.gg
Enrolling by invitationNCT06645431Updated Oct 16, 2024

Effect of Low Water Intake on Glucose Regulation Measured Using Continuous Glucose Monitoring

An interventional study of Water Intake in Blood Glucose Concentration and Blood Glucose Self Monitoring, sponsored by California Polytechnic State University-San Luis Obispo. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-16.

Sponsored by California Polytechnic State University-San Luis Obispo · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,023 studies in Diabetes Mellitus with a site in United States — 289 open to participants now, 388 under way, 12 of them phase 3. Diabetes Mellitus · United States.

Planned enrollment
2,024th of 2,502
20 · median 82
Started
2024
with 87 others
No phase
1,418 of 3,023
159 open now
Primary completion
2025-07
later than 24 of 380 live
Registered
2,834th of 3,023
by date

Among the 3,023 studies in Diabetes Mellitus with a site in United States, this one is the 2,024th largest by planned enrollment of the 2,502 interventional ones that give a count, is one of 88 that started in 2024, is one of 1,418 with no phase, reaches primary completion later than 24 of the 380 other live ones, and was the 2,834th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

289 of the 3,023 studies in Diabetes Mellitus with a site in United States are open now. Recruiting first, the newest first:

284 more — sign in →

All 289 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,023 studies in Diabetes Mellitus with a site in United States, or all of them as a file.
02

Study summary

This clinical trial aims to learn if increasing water intake for five days can lower blood glucose in healthy, free-living individuals. The main question it aims to answer is whether increasing water intake will reduce daily blood glucose. Researchers will compare blood glucose when drinking adequate water to when the same individuals drink a low amount of water to see if blood glucose differs with water intake. Participants will be asked to drink a prescribed volume of water over two weeks while wearing a continuous glucose monitor and collecting two urine voids throughout each day.

Read the detailed description

Twenty participants between 18 and 55 will be recruited from San Luis Obispo County using flyers, social media, local channels, and other online methods. Participants must be able to provide written and verbal consent to participate in the study. They must not currently be diagnosed with conditions, including, but not limited to, diabetes, pre-diabetes, pregnancy, and chronic illnesses. They must neither have received any surgery on their digestive tract nor be taking any oral contraceptives.

Surveys will be administered throughout the study consisting of validated surveys, which will be given out to participants via the encrypted data storage intermediary platform RedCap, which creates a unique identifier for each response to a survey and will be used to link responses across the study period for each participant. Participant's personal information will be password-protected and stored separately to be used for follow-up responses by Cal Poly investigators and research staff.

After participants complete the interest form and permit us to contact them, researchers will schedule the first visit to determine if participants are eligible, obtain consent for participation, and complete questionnaires assessing baseline physical activity, fluid intake, and diet. All participant visits will be scheduled through email or in person when the participant is on a prior visit to the laboratory. Any researcher contacting a participant for scheduling will use a Cal Poly email address and will only contact the participant's email provided in the interest form. Any scheduling email sent will follow the attached script. The second visit will occur in person and mark the start of the first six-day intervention. During this visit, researchers will place the continuous glucose monitor and Gene Active sensor and provide participants with resealable containers for urine collection and concealed bags to transport urine samples to the laboratory. Participants will be assigned to treatments in a counterbalanced fashion. For six days, participants will consume either the NAM's recommended total water intake of 2.7 liters per day for women and 3.7 liters per day for men (high water intake group, HWI) or 0.7 liters per day for women and 1 liter per day for men (low water intake group, LWI). Participants will be allowed to consume fluid ad libitum for four days. For the second six days, participants will consume either HWI or LWI, depending on the treatment completed in the first five days. Participants cannot drink fluids other than water and coffee/tea if requested. Water bottles will be provided with the prescribed amount of water for each day. Participants will collect two urine samples daily: a first-morning sample upon waking and an afternoon sample (2:00 PM-5:00 PM). Participants will deliver their urine containers to the laboratory every other day. Urine samples will be analyzed for specific gravity and volume.

In Redcap, participants will complete a daily mood disturbance questionnaire and a weekly solid food-to-water questionnaire. They will also complete daily food fluid intake questionnaires. This will include a urine void survey, where participants will track the number of times they urinated each day. Participants will be asked to align their food intake during the second five-day intervention with the same foods and amounts consumed during the first five-day intervention. During the four-day washout period, participants can eat however they want.

03

Conditions studied

  • Blood Glucose Concentration
  • Blood Glucose Self Monitoring

Browse trials for

Keywords

  • Hydration
  • Blood Glucose
  • Water Intake
  • Diabetes
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-55 years
  • able to provide written and verbal consent

Exclusion criteria

Exclusion Criteria:

  • diabetes
  • pre-diabetes
  • pregnancy
  • chronic illness
  • No past surgery on the digestive tract
  • taking any oral
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    High water intake

    For six days, participants will consume the NAM's recommended total water intake of 2.7 liters per day for women and 3.7 liters per day for men

    Behavioral: Water Intake

  • Active comparator
    Low water intake

    For six days, participants will consume 0.7 liters per day for women and 1 liter per day for men.

    Behavioral: Water Intake

Interventions

  • BehavioralWater Intake

    Previous studies have not observed blood glucose with adequate vs. low water intake in a free-living situation. The use of continuous glucose monitors allows this.

06

What researchers measure

Primary outcomes

  1. Daily blood glucose

    Area under the curve of daily blood glucose

    Time frame: 14 days

Secondary outcomes

  1. Urine specific gravity

    Urine concentration

    Time frame: 14 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Jul 2025, 9 months after the start.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 9 months is below that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2024
First posted
Oct 16, 2024
StartActual
Oct 1, 2024
Primary completionEst.
Jul 31, 2025
CompletionEst.
Aug 2025
Last update
Oct 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06645431
Lead sponsor
California Polytechnic State University-San Luis Obispo
Responsible party
Adam Seal (Principal Investigator, California Polytechnic State University-San Luis Obispo) — Principal investigator
First posted
Oct 16, 2024
Start date
Oct 1, 2024
Primary completion
Jul 31, 2025 (estimated)
Completion
Aug 2025 (estimated)
Last update
Oct 16, 2024

Study contacts

Adam D Seal, Ph.D.
principal investigator · California Polytechnic State University-San Luis Obispo

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion